Morgan Stanley

March 1, 2012

India Strategy: Mid-cap List Adding DITV and INFTC

Adding DITV and INFTC

We are adding Dish TV and Infotech Enterprise to our Mid-cap list. Effectively, we are increasing the number of stocks in our mid-cap list to 12 from 10.

Continue to favor stock picking

Our sector calls remain narrow given our view that this is a stock-pickers' market. We reiterate our preference for domestic over global cyclicals. Consumer Discretionary is our favored rate-sensitive sector. We continue to choose mid-caps over large caps given the valuation gap. Top avoids remain Materials and SOE Banks.

MORGAN STANLEY RESEARCH Asia/Pacific

Morgan Stanley India Company Private Limited+

Ridham Desai

+91 22 6118 2222

Sheela Rathi

+91 22 6118 2224

Amruta Pabalkar

+91 2261182225

Utkarsh Khandelwal

+91 22 6118 2226

Subscribe to India Strategy Research

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

+= Analysts employed by non-U.S. affiliates are not registered with FINRA, may not be associated persons of the member and may not be subject to NASD/NYSE restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Mid-cap List: Adding DITV and INFTC

Why are we adding Dish TV to our mid-cap list?

- Amongst the biggest gainers from ongoing digitization in India We expect DTIL to grow its gross subscriber base at a healthy CAGR of 18.9% from F2012-14 to reach 19.8mn by F2014. Also, if the government were to diligently enforce the digitization rollout, there could be a potential upside to our growth assumptions.
- We expect the valuation to see upside based on improving ARPU and cost trends, which will drive margin expansion for DTIL.
 - Competitive pressures have led to tepid ARPU growth over the last six months for DTIL. We expect other DTH players to shift their focus toward profitability at the same time we expect greater consumer willingness to pay for digital content. This is expected to drive ARPU growth. We expect ARPU CAGR of 12% over F2012-14.
 - We expect DTIL's cost structure to be rationalized as it is spread over an increasing subscriber base. Programming cost as a % of revenue is expected to drop to 30% in F2014 from 35% in F2011 and 32% in F2012e.
 - We expect an EBITDA CAGR of 45% from F2012-14e.
- Currently, the stock trades at an EV/EBITDA of 8.3x based on our F2013 estimates.

Why are we adding Infotech Enterprise to our mid-cap list?

• Risk-reward remains favorable: Infotech stock is currently trading at 8.6x F2013e EPS, ~20% discount to its 8-10 year historical average. This may reflect concerns that USD revenue growth would slow down significantly to 14-15% yoy in F2013e (vs. 25% in F2012e) based on consensus estimates. We expect Infotech to continue to deliver strong USD revenue growth of ~19% in F2013, helped by stable 2012 budgets for its clients, expectations of price increases in the current environment, and ramp up of new accounts. Overall, we expect Infotech to grow revenues and earnings at a CAGR of 20% over F2012-14.

- Infotech stock has risen ~36% YTD (vs. the 15% gain in the Sensex). However, over the last year, the stock is still underperforming Sensex and its other mid-cap peers. The stock is up 17% (vs. ~8% for the Sensex) since announcing its F3Q12 results (January 18, 2012) as concerns about margins eased after it reported stronger-than-expected margin improvement. We believe Infotech stock has further upside potential and should continue to outperform once revenue growth concerns ease for the company over the coming quarters.
- Improved volume growth, robust hiring in 4Q (strongest in the last few quarters) and a stable hiring outlook for F2013 are the key catalysts that should help ease concerns on revenue growth, in our view.

Focus List and Sector Model Portfolio Performance

- Year to date, our sector model portfolio has outperformed the MSCI India index by 13bp and our Focus List has outperformed the BSE Sensex by 375bp. Our mid-cap list has outperformed BSE Midcap by 104bp.
- We are not making changes to our sector model portfolio. We are
 Overweight Consumer Discretionary and Technology and
 Underweight Financials, Industrials, Materials and Telecoms. We are
 Neutral on Consumer Staples, Energy, Healthcare and Utilities.

Focus List and Mid-cap List

Focus List

Stocks	Sector	Ticker	Analyst Rating	Price (Rs) Feb 29, 2012			Relative to Sensex	
					MCap (US\$ bn)	Avg 3M T/O (US\$ mn)	YTD Perf	12m Perf
Bajaj Auto	Consumer Disc	BJAUT IN	OW	1,799	10.4	3	-2%	42%
Cox & Kings	Consumer Disc	COXK IN	OW	173	0.5	2	-2%	-12%
M&M	Consumer Disc	MM IN	EW	708	9.1	38	-10%	16%
Tata Motors A	Consumer Disc	TTMT/A IN	OW	153	1.5	7	54%	28%
ZEE Enter.	Consumer Disc	Z IN	EW	127	2.6	4	-6%	7%
Coal India	Energy	COAL IN	OW	333	42.0	31	-4%	2%
ICICI Bank	Financials	ICICIBC IN	EW	907	21.8	111	15%	-6%
Oberoi Realty	Financials	OBER IN	OW	284	1.8	0	19%	31%
Dr. Reddy's	Healthcare	DRRD IN	OW	1,639	5.6	13	-10%	6%
Adani Ent	Industrials	ADE IN	OW	374	8.4	16	11%	-38%
IRB Infra	Industrials	IRB IN	OW	184	1.2	6	24%	0%
Jain Irrigation	Industrials	JI IN	OW	108	0.9	7	8%	-41%
Tata Steel	Materials	TATA IN	OW	472	9.3	64	23%	-22%
Infosys	Technology	INFO IN	OW	2,875	34.2	73	-9%	-4%
Wipro	Technology	WPRO IN	OW	432	21.7	14	-6%	-1%

Mid-cap List


	Sector		Analyst Rating	Price (Rs) Feb 29, 2012			Relative to	BSE Midcap
Stocks		Ticker			MCap (US\$ bn)	Avg 3M T/O (US\$ mn)	YTD Perf	12m Perf
Cox & Kings	Consumer Disc	COXK IN	OW	173	0.5	2	-10%	-13%
Dish TV	Consumer Disc	DITV IN	EW	54	1.2	7	-26%	-8%
Hathw ay	Consumer Disc	HATH IN	OW	166	0.5	2	22%	39%
Tata Motors DVR	Consumer Disc	TTMT/A IN	OW	153	1.5	7	42%	27%
Marico	Consumer Staples	MRCO IN	OW	158	2.0	1	-13%	33%
Oberoi Realty	Financials	OBER IN	OW	284	1.8	0	9%	30%
IRB Infra	Industrials	IRB IN	OW	184	1.2	6	14%	0%
Jain Irrigation	Industrials	JI IN	OW	108	0.9	7	0%	-42%
United Phosp	Materials	UNTP IN	OW	155	1.4	4	-2%	14%
Infotech Enter	Technology	INFTC IN	OW	148	0.3	0	9%	-7%
Mindtree Ltd.	Technology	MTCL IN	OW	465	0.4	1	-6%	26%
OnMobile Global	Telecoms	ONMB IN	OW	71	0.2	2	-10%	-29%

Sector Positions and Performance


Sector Model Portfolio

Sector	MSCI	Portfolio	Over/Under -	Perf Rel. To MSCI India			
	Weight (%)	Weight (%)	Weight (bps)	(YTD)	(12M)		
MSCI India				17%	-1%		
Consumer Disc.	8.5	11.5	300	7%	47%		
Consumer Staples	7.3	7.3	0	-13%	18%		
Energy	12.0	12.0	0	-2%	-11%		
Financials	26.6	25.6	-100	7%	5%		
Healthcare	4.8	4.8	0	-9%	14%		
Industrials	6.3	5.3	-100	13%	-23%		
Technology	17.0	18.0	100	-10%	0%		
Materials	9.9	8.9	-100	9%	-10%		
Telecoms	2.5	1.5	-100	-8%	-17%		
Utilities	5.1	5.1	0	3%	-1%		
Cash	-	-					


Focus List Performance since Launch



Sector Model Portfolio Performance Since Launch



Mid-cap List Performance since Launch



Focus List Timeline Since Inception

		Date Added	Dated Removed	Sensex on date added	Sensex on date when removed or current	Stock price w hen Added	Price w hen removed or current price	Dividend if any	Stock return*	Returns relative to Sensex
ADE IB Equity	Adani Enterprise	15-Apr-11		19387	17753	643	374	1	-42%	-36%
BJAUT IB Equity	Bajaj Auto	18-Aug-11		16470	17753	1438	1799	46	25%	16%
COAL IB Equity	Coal India	18-Aug-11		16470	17753	391	333	5	-15%	-21%
COXK IB Equity	Cox & Kings	13-Jun-11		18266	17753	214	173	1	-19%	-17%
DRRD IB Equity	Dr. Reddy's	14-Jun-11		18309	17753	1555	1639	11	5%	9%
ICICIBC IB Equity	ICICI Bank	21-Mar-11		17839	17753	1006	907	16	-10%	-9%
NFO IB Equity	Infosys	15-Apr-11		19387	17753	2989	2875	70	-4%	5%
RB IB Equity	IRB Infra	13-Jun-11		18266	17753	176	184	2	5%	8%
JI IB Equity	Jain Irrigation	10-Aug-11		17131	17753	162	108	1	-34%	-36%
VIM IB Equity	M&M	15-Apr-11		19387	17753	724	708	13	-2%	7%
OBER IB Equity	Oberoi Realty	6-Sep-11		16863	17753	225	284	О	26%	20%
TTMT/A IB Equity	Tata Motors DVR	27-Feb-12		17446	17753	135	153	-	13%	11%
TATA IB Equity	Tata Steel	15-Apr-11		19387	17753	630	472	12	-25%	-18%
WPRO IB Equity	Wipro	13-Jan-12		16155	17753	401	432	7	8%	-2%
Z IB Equity	ZEE Entertainment	10-Aug-11		17131	17753	127	127	2	0%	-4%
DLFU IB Equity	DLF	15-Jul-09	6-Sep-11	14253	16863	322	199	5	-38%	-48%
ACC IB Equity	ACC	19-Aug-10	15-Apr-11	18455	19387	881	1111	29	26%	20%
ADANI IB Equity	Adani Pow er	28-Apr-10	21-Mar-11	17380	17839	119	111	О	-7%	-9%
ARVND IB Equity	Arvind Ltd.	22-Aug-07	4-Dec-08	14249	9230	43	15	_	-65%	-47%
3HARTI IB Equity	Bharti Airtel	22-Aug-07	15-Jul-09	14249	14253	424	390	1	-8%	-8%
BHARTI IB Equity	Bharti Airtel	28-Apr-10	27-Feb-12	17380	17446	295	341	1	16%	15%
CAIR IB Equity	Cairn India	22-Sep-09	10-Aug-11	16886	17131	263	273	О	18%	22%
CIPLA IB Equity	Cipla Ltd.	4-Dec-08	15-May-09	9230	12173	184	231	2	25%	-5%
COAL IB Equity	Coal India	18-Jan-11	14-Jun-11	19092	18309	311	395	5	27%	32%
GAIL IB Equity	GAIL (India)	22-Aug-07	29-Nov-07	14249	19003	199	279	10	40%	5%
GAIL IB Equity	GAIL (India)	21-Mar-11	13-Jan-12	17839	16155	451	373	8	-17%	-8%
HDFC IB Equity	HDFC	22-Aug-07	29-Jun-10	14249	17534	1901	2902	34	53%	24%
HUVR IB Equity	Hindustan Unilever	21-Aug-08	6-Nov-09	14244	16158	236	273	11	16%	2%
NFO IB Equity	Infosys Tech	29-Nov-07	1-Dec-09	19003	17198	1570	2395	27	53%	69%
TC IB Equity	пс	6-Nov-09	19-Aug-10	16158	18455	124	165	2	33%	16%
JPA IB Equity	Jaiprakash Asso.	29-Nov-07	18-Aug-11	19003	16470	241	58	1	-76%	-72%
T IB Equity	Larsen & Toubro	15-May-09	18-Aug-11	12173	16470	988	1625	17	64%	22%
MRCO IB Equity	Marico	22-Aug-07	15-May-09	14249	12173	58	63	1	9%	28%
VINCO IB Equity VISIL IB Equity	Maruti Suzuki	15-May-09	28-Apr-10	12173	17380	848	1271	4	50%	5%
ONGC IB Equity	ONGC	22-Aug-07	22-Sep-09	14249	16886	809	1155	34	43%	21%
RBXY IB Equity	Ranbaxy Lab	1-Dec-09	2-Nov-10	17198	20346	469	602	12	28%	8%
RIL IB Equity	Reliance Industries	22-Aug-07	7-Jul-11	14249	19078	884	870	8	-2%	-26%
RELIBEQUITY	Reliance Industries	22-Aug-07 22-Aug-07	29-Nov-07	14249	19078	725	1664	7	-2% 130%	-26% 72%
RELI IB Equity	Reliance Infra	22-Aug-07 15-Jul-09	13-Jun-11	14253	18266	725 1104	543	11	-51%	-62%
SBIN IB Equity		13-Aug-09	21-Mar-11	15518	17839	1799	2583	59	-51% 44%	-62% 25%
	State Bank of India							3		
SESA IB Equity	Sesa Goa	29-Jun-10	18-Jan-11	17534 17151	19092	356	354	8	-1% -69%	-2%
SOBHA IB Equity	Sobha Developers	27-Sep-07	21-Aug-08		14244	856	264			-63%
SUNP IB Equity	Sun Pharmaceutical	22-Aug-07	15-Jul-09	14249	14253	922	1216	12	32%	32%
SUNP IB Equity	Sun Pharmaceutical	2-Nov-10	13-Jun-11	20346	18266	438	479	4	10%	22%
TTMT IB Equity	Tata Motors	7-Jul-11	10-Aug-11	19078	17131	1053	844	17	-20%	-11%
FATA IB Equity	Tata Steel	22-Aug-07	21-Aug-08	14249	14244	503	589	13	17%	17%
TCS IB Equity UNBK IB Equity	TCS	22-Aug-07	27-Sep-07	14249	17151	512	531	7	4%	-14%
	Union Bank	22-Aug-07	13-Aug-09	14249	15518	126	213	5	70%	56%

Source: FactSet, MSCI, Bloomberg, Morgan Stanley Research. Past performance is no guarantee of future results. Results shown do not include transaction costs

Please note performance of Cairn and Sesa Goa were considered up to 13 August 2010. Cairn was out of restriction on 20th Dec 2010. We have considered performance of Cairn from 20th December onwards. Morgan Stanley & Co. Limited is acting as financial adviser and sponsor to Vedanta Resources PLC ("Vedanta") on Vedanta Group's proposed acquisition of 51% to 60% of Cairn India Limited ("Cairn India"), as announced on 16 August 2010. Morgan Stanley & Co. International plc. is also Corporate Broker to Vedanta. In accordance with its general policy, Morgan Stanley expresses no rating or price target on Vedanta, Cairn India, Cairn Energy PLC or Sesa Goa Ltd. This report and the information herein are not intended to serve as an endorsement of the proposed transaction. This report was prepared solely upon information generally available to the public No representation is made that it is accurate and complete. This report is not a recommendation or an offer to buy or sell the securities mentioned. Please refer to the notes at the end of this report.

Mid-cap List Timeline Since Inception

				BSE Midcap	BSE Midcap on date w hen	Stock price	Price w hen			Returns relative to
		Date Added	Dated Removed	on date added	removed or current	w hen Added	removed or current price	Dividend if any	Stock return*	BSE Midcap
DITV IB Equity	Dish TV	29-Feb-12		6387	6387	54	54	-	-	-
INFTC IB Equity	Infotech Enter	29-Feb-12		6387	6387	148	148	-	-	-
COXK IB Equity	Cox & Kings	2-Nov-11		6254	6387	222	173	1	-22%	-24%
HATH IB Equity	Hathw ay	2-Nov-11		6254	6387	117	166	0	42%	39%
IRB IB Equity	IRB Infra	2-Nov-11		6254	6387	166	184	2	11%	9%
JI IB Equity	Jain Irrigation	2-Nov-11		6254	6387	117	108	1	-8%	-10%
MRCO IB Equity	Marico	13-Jan-12		5582	6387	152	158	1	4%	-9%
MTCL IB Equity	Mindtree Ltd.	2-Nov-11		6254	6387	395	465	5	18%	15%
OBER IB Equity	Oberoi Realty	2-Nov-11		6254	6387	233	284	0	22%	19%
ONMB IB Equity	OnMobile Global	2-Nov-11		6254	6387	57	71	0	24%	21%
TTMT/A IB Equity	Tata Motors DVR	27-Feb-12		6110	6387	135	153	-	13%	8%
UNTP IB Equity	United Phosp	2-Nov-11		6254	6387	144	155	2	8%	5%
GESCO IB Equity	Great Eastern Shipping	2-Nov-11	27-Feb-12	6254	6110	233	228	9	-2%	0%
PATNI IB Equity	Patni Computer	2-Nov-11	13-Jan-12	6254	5520	334	471	75	41%	60%



Morgan Stanley ModelWare is a proprietary analytic framework that helps clients uncover value, adjusting for distortions and ambiguities created by local accounting regulations. For example, ModelWare EPS adjusts for one-time events, capitalizes operating leases (where their use is significant), and converts inventory from LIFO costing to a FIFO basis. ModelWare also emphasizes the separation of operating performance of a company from its financing for a more complete view of how a company generates earnings.

Disclosures Section

The information and opinions in Morgan Stanley Research were prepared or are disseminated by Morgan Stanley Asia Limited (which accepts the responsibility for its contents) and/or Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research), and/or Morgan Stanley Taiwan Limited and/or Morgan Stanley & Co International plc, Seoul Branch, and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents), and/or Morgan Stanley Smith Barney Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents), and/or Morgan Stanley India Company Private Limited and their affiliates (collectively, "Morgan Stanley").

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any price targets referenced in this research report, please email morganstanley.research@morganstanley.com with a request for valuation methodology and risks on a particular stock or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Ridham Desai. Unless otherwise stated, the individuals listed on the cover page of this report are research analysts.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictpolicies.

Important US Regulatory Disclosures on Subject Companies

The following analyst or strategist (or a household member) owns securities (or related derivatives) in a company that he or she covers or recommends in Morgan Stanley Research: Ridham Desai - Dish TV India Ltd(common or preferred stock), Hindustan Unilever(common or preferred stock), Infosys Limited(common or preferred stock), ITC Ltd.(common or preferred stock), Zee Entertainment Enterprise Limited(common or preferred stock); Utkarsh Khandelwal - Mahindra & Mahindra (common or preferred stock), Reliance Infrastructure Limited(common or preferred stock); Amruta Pabalkar - Reliance Industries(common or preferred stock), State Bank of India(common or preferred stock), Tata Consultancy Services(common or preferred stock), Tata Steel(common or preferred stock), Union Bank of India(common or preferred stock). Morgan Stanley policy prohibits research analysts, strategists and research associates from investing in securities in their sub industry as defined by the Global Industry Classification Standard ("GICS," which was developed by and is the exclusive property of MSCI and S&P). Analysts may nevertheless own such securities to the extent acquired under a prior policy or in a merger, fund distribution or other involuntary acquisition.

As of January 31, 2012, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: Dr. Reddy's Lab, Infotech Enterprises, Jain Irrigation Systems, Mahindra & Mahindra, Oberoi Realty Limited, Sobha Developers Ltd., Tata Motors, Tata Steel

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from Coal India Limited, Hathway Cable and Datacom Ltd., Oberoi Realty Limited, Sesa Goa, Tata Motors.

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from ACC Ltd., Adani Enterprises Ltd, Bajaj Auto Ltd., Cairn India Ltd., Cox & Kings Ltd, DLF Limited, Dr. Reddy's Lab, HDFC, ICICI Bank, Jain Irrigation Systems, Jaiprakash Associates Limited, Larsen & Toubro, Mahindra & Mahindra, Marico Limited, MindTree Ltd., Oil & Natural Gas Corp., Patni Computer Systems, Ranbaxy Laboratories, Reliance Infrastructure Limited, Sesa Goa, State Bank of India, Sun Pharmaceutical Industries, Tata Consultancy Services, Tata Motors, Tata Steel, United Phosphorus Limited, Wipro Ltd., Zee Entertainment Enterprise Limited.

Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from Hathway Cable and Datacom Ltd., HDFC, ICICI Bank, Reliance Industries, State Bank of India, Tata Motors, Tata Steel.

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: ACC Ltd., Adani Enterprises Ltd, Bajaj Auto Ltd., Cairn India Ltd., Coal India Limited, Cox & Kings Ltd, DLF Limited, Dr. Reddy's Lab, Hathway Cable and Datacom Ltd., HDFC, ICICI Bank, Jain Irrigation Systems, Jaiprakash Associates Limited, Larsen & Toubro, Mahindra & Mahindra, Marico Limited, MindTree Ltd., Oberoi Realty Limited, Oil & Natural Gas Corp., Patni Computer Systems, Ranbaxy Laboratories, Reliance Industries, Reliance Infrastructure Limited, Sesa Goa, State Bank of India, Sun Pharmaceutical Industries, Tata Consultancy Services, Tata Motors, Tata Steel, United Phosphorus Limited, Wipro Ltd., Zee Entertainment Enterprise Limited.

Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: Great Eastern Shipping, Hathway Cable and Datacom Ltd., HDFC, ICICI Bank, MindTree Ltd., Patni Computer Systems, Ranbaxy Laboratories, Reliance Industries, State Bank of India, Tata Motors, Tata Steel, Union Bank of India. Morgan Stanley & Co. LLC makes a market in the securities of Dr. Reddy's Lab, ICICI Bank, Infosys Limited, Patni Computer Systems, Tata Motors, Wipro Ltd.. The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity and specialized trading, risk arbitrage and other proprietary trading, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of January 31, 2012)

For disclosure purposes only (in accordance with NASD and NYSE requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

	Coverage	Universe	Investment Banking Clients (IBC)				
				% of Total	% of Rating		
Stock Rating Category	Count	% of Total	Count	IBC	Category		
Overweight/Buy	1135	39%	460	44%	41%		
Equal-weight/Hold	1248	42%	444	42%	36%		
Not-Rated/Hold	107	4%	25	2%	23%		
Underweight/Sell	454	15%	121	12%	27%		
Total	2,944		1050				

Data include common stock and ADRs currently assigned ratings. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months.

Analyst Stock Ratings

Overweight (O or Over) - The stock's total return is expected to exceed the total return of the relevant country MSCI Index, on a risk-adjusted basis over the next 12-18 months.

Equal-weight (E or Equal) - The stock's total return is expected to be in line with the total return of the relevant country MSCI Index, on a risk-adjusted basis over the next 12-18 months.

Not-Rated (NR) - Currently the analyst does not have adequate conviction about the stock's total return relative to the relevant country MSCI Index on a risk-adjusted basis, over the next 12-18 months.

Underweight (U or Under) - The stock's total return is expected to be below the total return of the relevant country MSCI Index, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

Analyst Industry Views

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers

Citi Investment Research & Analysis (CIRA) research reports may be available about the companies or topics that are the subject of Morgan Stanley Research. Ask your Financial Advisor or use Research Center to view any available CIRA research reports in addition to Morgan Stanley research reports.

Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC, Morgan Stanley and Citigroup Global Markets Inc. or any of their affiliates, are available on the Morgan Stanley Smith Barney disclosure website at www.morganstanleysmithbarney.com/researchdisclosures. For Morgan Stanley and Citigroup Global Markets, Inc. specific disclosures, you may refer to www.morganstanley.com/researchdisclosures and https://www.citigroupgeo.com/geopublic/Disclosures/index_a.html.

Each Morgan Stanley Equity Research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the Equity Research report on behalf of Morgan Stanley. This could create a conflict of interest.

Other Important Disclosures

Morgan Stanley & Co. International PLC and its affiliates have a significant financial interest in the debt securities of HDFC, ICICI Bank, Ranbaxy Laboratories, Reliance Industries, Reliance Infrastructure Limited, State Bank of India, Tata Motors, Tata Steel.

Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Client Link at www.morganstanley.com.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell any security/instrument or to participate in any trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The "Important US Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments or companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

Morgan Stanley may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

To our readers in Taiwan: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. Information on any securities/instruments issued by a company owned by the government of or incorporated in the PRC and listed in on the Stock Exchange of Hong Kong ("SEHK"), namely the H-shares, including the component company stocks of the Stock Exchange of Hong Kong ("SEHK")'s Hang Seng China Enterprise Index is distributed only to Taiwan Securities Investment Trust Enterprises ("SITE"). The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. To our readers in Hong Kong: Information is distributed in Hong Kong by and on behalf of, and is attributable to, Morgan Stanley Asia Limited as part of its regulated activities in Hong Kong. If you have any queries concerning Morgan Stanley Research, please contact our Hong Kong sales representatives. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments. Certain information in Morgan Stanley Research was sourced by employees of the Shanghai Representative Office of Morgan Stanley Asia Limited for the use of Morgan Stanley Asia Limited.

Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A.; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd. in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents); in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with. Morgan Stanley Research); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Smith Barney Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc. Seoul Branch: in India by Morgan Stanley India Company Private Limited: in Canada by Morgan Stanley Canada Limited. which has approved of and takes responsibility for its contents in Canada; in Germany by Morgan Stanley Bank AG, Frankfurt am Main and Morgan Stanley Private Wealth Management Limited, Niederlassung Deutschland, regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin); in Spain by Morgan Stanley, S.V., S.A., a Morgan Stanley group company, which is supervised by the Spanish Securities Markets Commission (CNMV) and states that Morgan Stanley Research has been written and distributed in accordance with the rules of conduct applicable to financial research as established under Spanish regulations; in the US by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized and regulated by the Financial Services Authority, disseminates in the UK research that it has prepared, and approves solely for the purposes of section 21 of the Financial Services and Markets Act 2000, research which has been prepared by any of its affiliates. Morgan Stanley Private Wealth Management Limited, authorized and regulated by the Financial Services Authority, also disseminates Morgan Stanley Research in the UK. Private UK investors should obtain the advice of their Morgan Stanley & Co. International plc or Morgan Stanley Private Wealth Management representative about the investments concerned. RMB Morgan Stanley (Proprietary) Limited is a member of the JSE Limited and regulated by the Financial Services Board in South Africa. RMB Morgan Stanley (Proprietary) Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at Professional Clients only, as defined by the DFSA. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria to be a Professional Client.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA. As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided in accordance with a contract of engagement on investment advisory concluded between brokerage houses, portfolio management companies, non-deposit banks and clients. Comments and recommendations stated here rely on the individual opinions of the ones providing these comments and recommendations. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P. Morgan Stanley bases projections, opinions, forecasts and trading strategies regarding the MSCI Country Index Series solely on public information. MSCI has not reviewed, approved or endorsed these projections, opinions, forecasts and trading strategies. Morgan Stanley has no influence on or control over MSCI's index compilation decisions. Morgan Stanley Research or portions of it may not be reprinted, sold or redistributed without the written consent of Morgan Stanley. Morgan Stanley research is disseminated and available primarily electronically, and, in some cases, in printed form. Additional information on recommended securities/instruments is available on request.

Morgan Stanley has based its projections, opinions, forecasts and trading strategies regarding the MSCI Country Index Series solely on publicly available information. MSCI has not reviewed, approved or endorsed the projections, opinions, forecasts and trading strategies contained herein. Morgan Stanley has no influence on or control over MSCI's index compilation decisions.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Morgan Stanley Research is disseminated and available primarily electronically, and, in some cases, in printed form.

Additional information on recommended securities/instruments is available on request.

The Americas 1585 Broadway New York, NY 10036-8293

United States +1 212 761 4000

Europe

20 Bank Street, Canary Wharf London E14 4AD United Kingdom +44 (0)20 7425 8000

Japan

4-20-3 Ebisu, Shibuya-ku Tokyo 150-6008 Japan +81 (0) 3 5424 5000

Asia/Pacific

1 Austin Road West Kowloon Hong Kong +852 2848 5200